KimForest Enterprise Co., Ltd. started the Precision Medicine Laboratory in 2017. In 2020, we have certified as a Laboratory Developed Test (LDTS) provider by Taiwan Food and Drug Administration (TFDA).
KimForest Enterprise Co., Ltd. provides comprehensive genetic testing services, including 523 gene panels. Our latest service is the hematologic malignancy genetic testing, targeted next-generation sequencing (NGS) assay designed to detect somatic variants in myeloid cancer using blood or bone marrow samples. This enables us to provide physicians and patients with the best possible treatment recommendations.
We offer highly accurate genetic testing services for myeloid cancer, analyzing gene hotspot mutations, short fragment insertions or deletions (Indels), and fusion variations. By leveraging the drug-gene analysis system, we can provide the best suggestion reference report for each case.